William Cefalu, MD
Internal Medicine · Morgan City, LANPI 1780908780
Payments from drug & device makers
Across 545 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$986
- Pfizer$864
- GSK$838
- AstraZeneca$741
- Lilly USA, LLC$623
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,486100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 107 | $1,633 |
| Novo Nordisk | 74 | $986 |
| Pfizer | 47 | $864 |
| GSK | 52 | $838 |
| AstraZeneca | 49 | $741 |
| Lilly USA, LLC | 42 | $623 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $318 |
| Boehringer Ingelheim | 20 | $297 |
| Amgen | 17 | $269 |
| Novartis | 16 | $269 |
| Esperion Therapeutics, Inc. | 16 | $263 |
| Sanofi-aventis U.S. LLC | 12 | $174 |
| Teva Pharmaceuticals USA, Inc. | 9 | $151 |
| Amarin Pharma, Inc. | 9 | $150 |
| Arbor Pharmaceuticals, Inc. | 9 | $138 |
| Bayer | 7 | $115 |
| Johnson & Johnson | 6 | $93 |
| Exact Sciences | 4 | $82 |
| Corium, LLC | 4 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $50 |
| Abbott | 3 | $49 |
| Redhill Biopharma Inc. | 2 | $38 |
| Eisai Inc. | 2 | $35 |
| Shire North American Group Inc | 2 | $33 |
| Merck | 2 | $30 |
| Circassia Inc. | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Medtronic | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$8,501 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 299 | $332,541 |
| OzempicSemaglutide | 102 | $132,583 |
| JardianceEmpagliflozin | 148 | $126,314 |
| EliquisApixaban | 207 | $91,446 |
| TrulicityDulaglutide | 83 | $83,743 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $81,849 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 91 | $54,543 |
| FarxigaDapagliflozin Propanediol | 86 | $49,790 |
| CreonLipase/Protease/Amylase | 19 | $32,515 |
| TradjentaLinagliptin | 49 | $31,718 |
| Tresiba Flextouch U-100Insulin Degludec | 43 | $30,026 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $25,673 |
| ProliaDenosumab | 13 | $22,763 |
| JanuviaSitagliptin Phosphate | 26 | $21,591 |
| LinzessLinaclotide | 22 | $18,638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $623 | $416,285382 claims |
| Boehringer IngelheimJardiance, Tradjenta | $297 | $158,032197 claims |
| Novo NordiskOzempic | $986 | $132,583102 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $838 | $104,891168 claims |
| PfizerEliquis | $864 | $91,446207 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $741 | $65,655108 claims |
| AbbVieCreon, Linzess, Synthroid | $1,633 | $56,13399 claims |
| AmgenProlia | $269 | $22,76313 claims |
| MerckJanuvia | $30 | $21,59126 claims |
| NovartisEntresto | $269 | $11,76329 claims |
| Johnson & JohnsonXarelto | $93 | $8,99318 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $8,48529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Morgan City
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.